Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have progressive metastatic differentiated thyroid cancer.

Key facts

Study ID

NCT00061906

Run by

Ohio State University Comprehensive Cancer Center

People needed

25

Starts

2003-01-01

Expected to finish

2006-06-01

Last updated by the study team

2014-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Ohio State University Comrehensive Cancer Center — Columbus, Ohio, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.